248 related articles for article (PubMed ID: 34127329)
1. Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma.
Hirono S; Kawai M; Okada KI; Miyazawa M; Kitahata Y; Kobayashi R; Hayami S; Ueno M; Yamaue H
Eur J Surg Oncol; 2021 Oct; 47(10):2586-2594. PubMed ID: 34127329
[TBL] [Abstract][Full Text] [Related]
2. Left posterior approach pancreaticoduodenectomy with total mesopancreas excision and circumferential lymphadenectomy around the superior mesenteric artery for pancreatic head carcinoma.
Aimoto T; Mizutani S; Kawano Y; Matsushita A; Yamashita N; Suzuki H; Uchida E
J Nippon Med Sch; 2013; 80(6):438-45. PubMed ID: 24419715
[TBL] [Abstract][Full Text] [Related]
3. Correspondence regarding "Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma".
Vasavada B
Eur J Surg Oncol; 2022 Jan; 48(1):302. PubMed ID: 34802861
[No Abstract] [Full Text] [Related]
4. Reply to: Correspondence reading "Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma".
Hirono S; Yamaue H
Eur J Surg Oncol; 2022 Jan; 48(1):300-301. PubMed ID: 34819244
[No Abstract] [Full Text] [Related]
5. Para-aortic lymph nodes and ductal adenocarcinoma of the pancreas: Distant neighbors?
Safi SA; Rehders A; Haeberle L; Fung S; Lehwald N; Esposito I; Ziayee F; Krieg A; Knoefel WT; Fluegen G
Surgery; 2021 Dec; 170(6):1807-1814. PubMed ID: 34392977
[TBL] [Abstract][Full Text] [Related]
6. Complete Lymphadenectomy Around the Entire Superior Mesenteric Artery Improves Survival in Artery-First Approach Pancreatoduodenectomy for T3 Pancreatic Ductal Adenocarcinoma.
Kobayashi S; Otsubo T; Nakano H; Koizumi S; Nakahara K
World J Surg; 2021 Mar; 45(3):857-864. PubMed ID: 33174091
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Matsunaga Y; Shiihara M; Yamamoto M
Pancreatology; 2021 Apr; 21(3):581-588. PubMed ID: 33579600
[TBL] [Abstract][Full Text] [Related]
8. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Oba A; Ban D; Kirimura S; Akahoshi K; Mitsunori Y; Matsumura S; Ochiai T; Kudo A; Tanaka S; Minoru T
J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):480-8. PubMed ID: 27247050
[TBL] [Abstract][Full Text] [Related]
9. Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety.
Inoue Y; Saiura A; Oba A; Kawakatsu S; Ono Y; Sato T; Mise Y; Ishizawa T; Takahashi Y; Ito H
J Gastrointest Surg; 2019 Jul; 23(7):1373-1383. PubMed ID: 30306451
[TBL] [Abstract][Full Text] [Related]
10. [The Clinical Efficacy of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Carcinoma--Report of Two Cases Treated by Curative Pancreatectomy with Portal Vein Resection after Neoadjuvant Chemotherapy].
Imamura T; Ikoma H; Morimura R; Hatakeyama T; Kosuga T; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Otsuji E
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2379-81. PubMed ID: 26805370
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma.
Suzuki T; Mori S; Shimizu T; Tago K; Harada N; Park KH; Sakuraoka Y; Shiraki T; Iso Y; Aoki T; Kubota K
In Vivo; 2019; 33(6):2027-2035. PubMed ID: 31662534
[TBL] [Abstract][Full Text] [Related]
12. The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy.
Yamada D; Eguchi H; Iwagami Y; Asaoka T; Noda T; Kawamoto K; Gotoh K; Kobayashi S; Mori M; Doki Y
Surg Today; 2018 Oct; 48(10):952-962. PubMed ID: 29770847
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival after resection of pancreatic ductal adenocarcinoma with para-aortic lymph node metastasis: case report.
Masui T; Kubota T; Aoki K; Nakanishi Y; Miyamoto T; Nagata J; Morino K; Fukugaki A; Takamura M; Sugimoto S; Onuma H; Tokuka A
World J Surg Oncol; 2013 Aug; 11(1):195. PubMed ID: 23945441
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcome of Patients with Postoperative Refractory Diarrhea After Tailored Nerve Plexus Dissection Around the Major Visceral Arteries During Pancreatoduodenectomy for Pancreatic Cancer.
Kuroki N; Ono Y; Sato T; Inoue Y; Oba A; Ito H; Mise Y; Saiura A; Takahashi Y
World J Surg; 2022 May; 46(5):1172-1182. PubMed ID: 35119513
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of Lymph Node Metastasis and Micrometastasis Along the Left Side of Superior Mesenteric Artery in Pancreatic Head Cancer.
Okada K; Murakami Y; Kondo N; Uemura K; Nakagawa N; Seo S; Takahashi S; Sueda T
J Gastrointest Surg; 2019 Oct; 23(10):2100-2109. PubMed ID: 31410820
[TBL] [Abstract][Full Text] [Related]
16. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomized controlled trial of 354 patients with pancreatic ductal adenocarcinoma.
Hirono S; Kawai M; Okada KI; Fujii T; Sho M; Satoi S; Amano R; Eguchi H; Mataki Y; Nakamura M; Matsumoto I; Baba H; Tani M; Kawabata Y; Nagakawa Y; Yamada S; Murakami Y; Shimokawa T; Yamaue H
Trials; 2018 Nov; 19(1):613. PubMed ID: 30409152
[TBL] [Abstract][Full Text] [Related]
17. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.
Katz MH; Wang H; Balachandran A; Bhosale P; Crane CH; Wang X; Pisters PW; Lee JE; Vauthey JN; Abdalla EK; Wolff R; Abbruzzese J; Varadhachary G; Chopin-Laly X; Charnsangavej C; Fleming JB
J Gastrointest Surg; 2012 Jan; 16(1):68-78; discussion 78-9. PubMed ID: 22065318
[TBL] [Abstract][Full Text] [Related]
18. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.
Jones RP; Psarelli EE; Jackson R; Ghaneh P; Halloran CM; Palmer DH; Campbell F; Valle JW; Faluyi O; O'Reilly DA; Cunningham D; Wadsley J; Darby S; Meyer T; Gillmore R; Anthoney A; Lind P; Glimelius B; Falk S; Izbicki JR; Middleton GW; Cummins S; Ross PJ; Wasan H; McDonald A; Crosby T; Ting Y; Patel K; Sherriff D; Soomal R; Borg D; Sothi S; Hammel P; Lerch MM; Mayerle J; Tjaden C; Strobel O; Hackert T; Büchler MW; Neoptolemos JP;
JAMA Surg; 2019 Nov; 154(11):1038-1048. PubMed ID: 31483448
[TBL] [Abstract][Full Text] [Related]
19. Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma.
Liu L; Katz MH; Lee SM; Fischer LK; Prakash L; Parker N; Wang H; Varadhachary GR; Wolff RA; Lee JE; Pisters PW; Maitra A; Fleming JB; Estrella J; Rashid A; Wang H
Am J Surg Pathol; 2015 Oct; 39(10):1395-403. PubMed ID: 26200098
[TBL] [Abstract][Full Text] [Related]
20. Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.
Aoyama T; Murakawa M; Katayama Y; Shiozawa M; Ueno M; Morimoto M; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Hepatogastroenterology; 2015; 62(138):472-7. PubMed ID: 25916085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
